Microglia enhanced the angiogenesis, migration and proliferation of co-cultured RMECs

Xinyi Ding, Ruiping Gu, Meng Zhang, Hui Ren, Qinmeng Shu, Gezhi Xu and Haixiang Wu

Abstract

Background: Attention is increasingly being given to microglia-related inflammation in neovascular diseases, such as diabetic retinopathy and age-related macular disease. Evidence shows that activated microglia contribute to disruption of the blood–retinal barrier, however, the mechanism is unclear. In this study, we aimed to clarify whether and how microglia affect the function of retinal microvascular endothelial cells (RMECs).

Methods: We activated microglia by Lipopolysaccharides (LPS) stimulation. After co-culturing static or activated microglia with RMECs using the Transwell system, we evaluated the function of RMECs. Vascular endothelial growth factor-A (VEGF-A) and platelet-derived growth factor-BB (PDGF-BB) levels in the supernatant from the lower chamber were evaluated by ELISA. Angiogenesis, migration, and proliferation of RMECs were assessed by tube formation, wound healing, and WST-1 assays. The expression levels of tight junction proteins (ZO-1 and occludin) and endothelial markers (CD31 and CD34) were examined by Western blot analysis.

Results: We successfully established an LPS-activated microglia model and co-culture system of static or activated microglia with RMECs. In the co-culture system, we showed that microglia, especially activated microglia stimulated VEGF-A and PDGF-BB expression, enhanced angiogenesis, migration, proliferation, and permeability, and altered the phenotype of co-cultured RMECs.

Conclusions: Microglia, especially activated microglia, play important roles in angiogenesis and maintenance of vascular function hemostasis in the retinal microvasculature. The mechanism needs further investigation and clarification.

Keywords: Microglia, Retinal microvascular endothelial cells, Angiogenesis, Inflammation, Retinopathy

Background

Microglia are important immune cell residents of the central nervous system, as well as the retina [1]. Microglial activation is involved in many important retinopathies, including light-induced photoreceptor degeneration, uveitis, age-related macular degeneration (AMD), and diabetic retinopathy [2–5].

Vascular endothelial cells are key components involved in the blood–retina barrier function and angiogenesis. Increased levels of blood glucose, advanced glycosylation end products (AGEs), and oxidative stress in diabetes drastically alter endothelial cell metabolism and induce endothelial cell dysfunction [6].

Increasing attention has recently been given to microglia-related inflammation in neovascular diseases, both in the central nervous system (CNS) and the retina. For example, it has been reported that diabetic retinopathy is closely related to retinal microvascular system damage, such as breakdown of the blood–retina barrier and angiogenesis and activation of hyperglycemia and/or hypoxia [7]. Recent studies have shown that retinal inflammation also contributes to the pathogenesis of...
diabetic retinopathy, and that activated microglia are present during the early stages of diabetic retinopathy and cluster in the retinal microvasculature [8–13]. However, the mechanism by which microglia affect retinal microvascular pericytes and endothelial cells needs further clarification. In our previous study, we showed that activated microglia induce production of reactive oxygen species (ROS) and promote apoptosis in co-cultured retinal microvascular pericytes [14]. Thus, in this study, we aimed to clarify whether microglia affect the functions of RMECs such as angiogenesis, migration, and proliferation.

Methods

RMECs culture

Rat primary RMECs were purchased from the Cell Biologics Company (catalogue no. RA-6065; Chicago, IL, USA). The cell line was recovered and cultured in accordance with the supplier’s instructions. Cells from passages 4–10 were used in this study.

Primary retinal microglia culture

Microglia were isolated from the retinas of newborn Sprague–Dawley rats. Newborn Sprague–Dawley rats (1–3 days old) were obtained from the Shanghai SLAC Laboratory Animal Company, and were sacrificed by decapitation. Treatment of animals was complied with the rules of the “Instruction and Administration of Experimental Animals,” and was approved by the Eye and ENT Hospital of Fudan University. The dissected retinas were collected and digested with 0.25 mg/mL trypsin at 37 °C. After 5 min, the trypsin was deactivated with DMEM/F12 (Gibco, Carlsbad, CA, USA) containing 20% FBS (Gibco) and 1% penicillin/streptomycin (Sigma-Aldrich, Billerica, MA, USA). The digested tissues were mechanically dissociated into a single cell suspension and collected by centrifugation. The cells were then resuspended in a DMEM: F12 (1:1) solution containing 20% FBS (Gibco) and 1% penicillin/streptomycin (Sigma-Aldrich, Billerica, MA, USA). For immunofluorescence assays, cell cultures were fixed with 4% paraformaldehyde in 0.01 M PBS for 10 min and then washed with PBS. After washing, the cultures were incubated in blocking buffer (5% normal goat serum) for 30 min at 37 °C. The cells were then incubated overnight at 4 °C with primary antibodies specific for markers of microglia (mouse OX42, 1:100, and mouse ED1, 1:100; Abcam, Cambridge, MA, USA) or RMECs (mouse anti-von Willebrand factor (vWF, 1:100; Abcam). After washing with PBS, the cells were incubated with the appropriate secondary antibodies for 30 min at 37 °C and counterstained with DAPI (1:1000; Molecular Probes/Thermo Fisher Scientific, Waltham, MA, USA). The labelled cells were examined by fluorescence microscopy (Leica Microsystems).

Flow cytometry

Isolated microglia were collected in DMEM/F12 containing 20% FBS and centrifuged for 10 min. After washing in PBS, the cell precipitate was resuspended in blocking solution (PBS containing 5% FBS and 1% BSA) and labelled with Alexa-Fluor-647-conjugated mouse anti-OX42 (1:100, Abcam, Cambridge, MA) for 15 min at 4 °C. The OX42-positive cells were counted by flow cytometry (Coulter Epics XL, Beckman-Coulter, Fullerton, CA).

Immunofluorescence assay

For immunofluorescence assays, cell cultures were fixed with 4% paraformaldehyde in 0.01 M PBS for 10 min and then washed with PBS. After washing, the cultures were incubated in blocking buffer (5% normal goat serum) for 30 min at 37 °C. The cells were then incubated overnight at 4 °C with primary antibodies specific for markers of microglia (mouse OX42, 1:100, and mouse ED1, 1:100; Abcam, Cambridge, MA, USA) or RMECs (mouse anti-von Willebrand factor (vWF, 1:100; Abcam). After washing with PBS, the cells were incubated with the appropriate secondary antibodies for 30 min at 37 °C and counterstained with DAPI (1:1000; Molecular Probes/Thermo Fisher Scientific, Waltham, MA, USA). The labelled cells were examined by fluorescence microscopy (Leica Microsystems).

Activation of microglia by LPS

The harvested microglia were seeded at 10⁶ cells/well in a six-well culture plate pre-coated with 20 μg/mL poly-d-lysine (Sigma-Aldrich). Twenty-four hours after seeding, each well was washed three times with 0.1 M PBS and incubated with culture medium containing 0, 0.1, 1, 10, 100, or 1000 ng/mL lipopolysaccharide (LPS) (Escherichia coli OB4:1111; Sigma-Aldrich) for 24 h.

Assessment of microglial viability

The effects of LPS on the viability of microglia were measured using the cell proliferation reagent water soluble tetrazolium-1 (WST-1; Roche, Basel, Switzerland). The WST-1 assay is based on the cellular reduction of WST-1 tetrazolium-1 (WST-1; Roche, Basel, Switzerland). The WST-1 assay was based on the cellular reduction of WST-1 by viable cells. Microglia were seeded in a 96-well microplate at 4 × 10³ cells/well in 100 μL culture medium containing 0, 0.1, 1, 10, 100, or 1000 ng/mL LPS. The cells were incubated for 48 h at 37 °C in 5% CO₂, and 10 μL WST-1 reagent was added to each well and incubated for 4 h at 37 °C in 5% CO₂. The plate was thoroughly shaken for 1 min on a shaker. To detect the production of formazan, the absorbance of each well at 420–480 nm was measured relative to the blank wells on a microplate reader.

Measurement of microglial cytokine concentrations

After exposure to LPS, the culture media was collected and centrifuged. Aliquots of the supernatant (50 μL) were collected to measure the concentrations of TNFα and IL-1β using enzyme-linked immunosorbent assay (ELISA) kits (R&D Systems, Minneapolis, MN, USA).

Transwell co-culture of microglia and RMECs

Freshly collected microglia were seeded onto 12-well Transwell collagen-coated membrane inserts (Corning Co.,
Corning, NY, USA). Separately, RMECs were grown to confluence in a collagen-coated 12-well plate. The microglia and RMECs were incubated in basal media for 24 h before co-culturing, and the Transwell inserts containing the retinal microglia (treated with or without LPS for 24 h) were placed into the wells containing RMECs. The 0.4 μm pore size of the Transwell prevents direct cell–cell interactions but allows the diffusion of soluble factors across the membrane (Fig. 1). After 24 h, the co-cultured cells were separated and cultured in fresh culture mediums for another 24 h, and then, the supernatant and cells were collected for further research. The experiment was divided into three groups: Con (RMECs without microglia), MG: (RMECs with static microglia), LPS-MG (RMECs with activated microglia).

Levels of angiogenesis-related growth factors in RMECs measured by ELISA
The supernatant of RMECs was collected and subjected to ELISA. The levels of vascular endothelial growth factor-A (VEGF-A) and platelet-derived growth factor-BB (PDGF-BB) were evaluated by sandwich ELISA (human VEGF-A and PDGF-BB ELISA kits, Abcam) according to the manufacturer’s instructions. Colorimetric analysis was performed and the absorbance was measured using an ELISA plate reader.

Tube formation assays
Tube formation assays were conducted on Matrigel (BD Biosciences, Franklin Lakes, NJ, USA). A 96-well plate was coated with 50 μL/well Matrigel at 37 °C for 30 min. After co-culturing with microglia for 24 h, RMECs were seeded on the Matrigel at 1.5 × 10^5 cells/well in 100 μL medium. After 4 h, tube formation was observed and photographed with a microscope (Leica Microsystems). Images were analyzed using ImageJ (NIH public domain), and four parameters were measured for quantification of tube formation: total tube length, number of nodes, number of branches, and total branch length.

Wound healing assays
RMECs were plated at a density of 10^4 in 24-well plates and grown to 100% confluence. To investigate the migration capability of RMECs, a wound was created by scratching the confluent monolayer down the middle of each well using a 10 μL pipette tip. Scratched RMECs were washed with PBS, and then 500 μL of fresh DMEM without serum was added to each well. Cells were imaged immediately after stimulation (0 h) and then at 6, 12, and 18 h after wounding. ImageJ software was utilized to determine the percentage of wound closure.

Assessment of RMEC proliferation
RMECs were collected and seeded in 96-well plates at 1 × 10^4 cells/well and treated with WST-1 for 4 h. The absorbance of the wells was read at 450 nm using the Benchmark Plus microplate reader to evaluate RMEC proliferation.

Phenotype and tight junction of RMECs
ZO-1 and occludin are markers of tight junctions in RMECs. CD31 and CD34 are markers of endothelial cells. RMECs were harvested, and the protein expression levels of zonula occludens-1(ZO-1), occludin, CD31 and CD34, were determined by Western blotting. After the proteins were transferred onto a PVDF membrane, the blots were incubated with primary antibodies (mouse anti-ZO-1, 1:100; mouse anti-occludin, 1:100; mouse anti-CD31, 1:100; mouse anti-CD34, 1:100; all from Abcam) and probed with a horseradish-peroxidase-conjugated secondary antibody. Protein expression was detected using an enhanced chemiluminescence kit. The density of each band was quantified using ImageQuant software (ImageQuant TL v. 7.0, GE Healthcare, Piscataway, NJ, USA). All samples were assayed in triplicate.

Statistical analysis
All statistical analyses were performed using GraphPad Prism 5.0. Measurement data were presented as x ± s. Differences between groups were evaluated using...
Effects of LPS on microglial morphology
To confirm LPS activation of microglia, the morphology of the microglia was evaluated. The purified microglia presented a static morphology with a branching shape, and immunofluorescence staining confirmed expression of CD11b/c and CD68 (by ED1) (Fig. 2E2). After treatment with 100 ng/mL LPS for 24 h, the microglia became rounder and larger, developing a characteristic amoeboid shape consistent with their activation (Fig. 2F1–F3), as we reported previously [14].

Effects of LPS on microglial viability
To confirm LPS activation of microglia, cell viability was evaluated using WST-1 reagent. At concentrations of 0.1–100 ng/mL, LPS did not significantly reduce cell viability. However, at 1000 ng/mL, LPS significantly reduced the viability of the microglia, indicating that 1000 ng/mL LPS has a cytotoxic effect on the microglia (Fig. 3a), as we reported previously [14]. Thus, we chose 100 ng/mL LPS to activate microglia, avoiding its cytotoxic effect on cells.

Effects of LPS on TNFα and IL-1β secretion from microglia
To confirm LPS activation of microglia, the pro-inflammatory factors of the microglia were evaluated. As shown in Fig. 3, TNFα and IL-1β were significantly overexpressed after adding 100 ng/mL LPS to the microglial culture medium. The TNFα and IL-1β levels were 3.22 ± 0.14 and 2.35 ± 0.08 times higher, respectively, than the levels in unstimulated microglia after 24 h LPS activation (Fig. 3b). Activation of microglia by LPS was shown by microglia morphology change and increased TNFα and IL-1β secretion.

Effects of static or activated microglia on the expression of angiogenesis-related factors in RMECs
After successfully establishing activated model of microglia, we co-cultured pretreated microglia with RMECs in the Transwell system to see the effects of microglia on RMECs. Freshly collected microglia were seeded onto 12-well Transwell collagen-coated membrane inserts (Corning Co., Corning, NY, USA) (treated with or without LPS for 24 h). Separately, RMECs were grown to confluence in a collagen-coated 12-well plate for 24 h. After co-culture for 24 h, as shown in Fig. 1, the cells were separated and cultured in fresh culture mediums for another 24 h, then then, the supernatant and cells were collected for further research. The experiment is divided into three groups: Con (RMECs without microglia), MG: (RMECs with static microglia), LPS-MG (RMECs with activated microglia).

The effects of microglia on the expression of angiogenesis-related factors in RMECs were evaluated by ELISA using the supernatant collected from the lower chamber. In the co-culture system, microglia significantly increased the release of VEGF-A and PDGF-BB from RMECs, compared to the RMECs without microglia. Furthermore, LPS-activated microglia enhanced the effects of static microglia on RMECs (Fig. 4). We conclude that microglia, especially activated microglia induced VEGF-A and PDGF-BB secretion of RMECs.

Effect of static or activated microglia on RMECs tube formation
Preprocessing and grouping of cells were as mentioned above. The effect of microglia on the angiogenesis ability of RMECs was measured with the tube formation assay, an important in vitro model for angiogenesis. As shown in Fig. 5, both static and activated microglia stimulated tube formation in the RMECs. In addition, the effects on RMECs tube formation were enhanced by the activated microglia compared with the static microglia (Fig. 5). The tube formation assay suggested that microglia, especially activated microglia induced the angiogenic abilities of RMECs.

Effect of static or activated microglia on RMECs migration
Preprocessing and grouping of cells were as mentioned above. The effect of microglia on RMEC migration was measured with the wound healing assay. As shown in Fig. 6, both static and activated microglia induced RMEC migration. Static microglia significantly stimulated wound recovery at 18 h, while activated microglia significantly stimulated wound recovery at 6, 12, and 18 h (Fig. 6). The wound healing assay revealed that microglia,
especially activated microglia increased the migration of RMECs.

**Effect of static or activated microglia on RMEC proliferation**

Preprocessing and grouping of cells were as mentioned above. The effect of microglia on RMECs proliferation was measured with WST-1 reagent. We found that both static and activated microglia induced RMEC proliferation, and LPS further enhanced the stimulatory effect of microglia on RMECs (Fig. 7a). The WST-1 assay showed that microglia, especially activated microglia promoted migration of RMECs.

**Effects of static or activated microglia on tight junctions and the phenotype of RMECs**

Preprocessing and grouping of cells were as mentioned above. For evaluation of the tight junction and phenotype
of RMECs, protein levels of occludin, ZO-1, CD-31, and CD-34 were measured with Western blotting. Both static and activated microglia significantly reduced the expression of tight junction occludin and ZO-1, markers of cell permeability, in RMECs compared with control cells. Regarding phenotype, both static and activated microglia significantly reduced CD31 and increased CD34 expression, which are endothelial markers, in RMECs (Fig. 7b). We concluded from these data that microglia, especially activated microglia, destroyed the tight junction of RMECs, which may contribute to the increased permeability of vasculature. In addition, microglia, especially activated microglia changed phenotype of RMECs, and the specific effect of these changes needs further investigation.

**Discussion**

The retinal microvasculature is composed of endothelial cells and pericytes. Diabetic retinopathy is first considered to be a simple microangiopathy. In the early stages of diabetic retinopathy, endothelial cell proliferation and pericytes apoptosis leads to damage of the blood-retinal barrier (BRB) [15].

Recently, new insights into retinal physiology have led to the emergence of the concept of the retinal neurovascular unit, [16–18] which is composed of retinal neurons (photoreceptors, horizontal, etc), their supporting cells (astrocytes and Müller glial cells), and the vascular beds (endothelial cells and pericytes). In diabetic retinopathy, metabolic alterations may first lead to glial dysfunction,
then induces inflammation, and neuronal apoptosis. Neurodegeneration also contributes to the breakdown of the blood–retinal barrier (BRB) [16, 17].

In addition, the role of microglia in diabetic retinopathy is currently of particular interest. However, the mechanisms by which the microglia affect the retinal microvascular pericytes and endothelial cells in diabetic retinopathy needs further clarification.

Combining our previous study with the present study, we showed that activated microglia increased oxidative stress damage and promoted apoptosis in pericytes; [14] and induced VEGF production, angiogenesis, migration, and proliferation. Activated microglia also destroyed the tight junction of endothelial cells affecting the integrity of the microvasculature, leading to BRB breakdown and contributing to neovascularization.

As the most important immune monitoring cell in the retina, microglia may manifest as static or activated states. It has been documented that microglia cells are abnormally activated in a variety of retinal diseases, including diabetic retinopathy [8, 19]. LPS stimulation is the most commonly used and effective method to activate microglia in vitro [20–22]. LPS could induce NF-κB activation and inflammatory cytokines release [23]. We initially used 100 ng/ml of LPS to successfully establish an activated model of microglia, which was proved by an increased expression of the pro-inflammatory cytokines TNFα and IL-1β and the typical morphological changes in the cells. In our study, we co-cultured static or activated microglia with RMECs using the Transwell co-culture system. After 24 h of co-culturing, we collected the RMECs to evaluate their functions. VEGF is a
key regulator among growth factors involved in angiogenesis [24]. VEGF-A is the most prevalent member of the VEGF family [25]. In addition to VEGF, PDGF is another well-studied angiogenic growth factor [26, 27]. PDGF-BB is the predominant isoform of the PDGF family expressed in the eye [28]. VEGF and PDGF have a synergic effect on vascular homeostasis [29, 30]. In the second part of our study, we found that microglia stimulate VEGF-A and PDGF-BB
expression in, and secretion from, RMECs, with an even stronger effect induced by activated microglia. As shown in the first part of the study, static microglia secreted basal levels of TNFα and IL-1β, which were markedly increased after activation by LPS. Thus, we hypothesize that TNFα and IL-1β function to stimulate VEGF-A and PDGF-BB, as suggested by previous studies [31, 32]. TNFα is able to increase the expression of VEGF, [33] stimulate NF-κB, JNK and p38 signaling pathways, [34, 35] all of which contribute to angiogenic activity [36]. IL-1β induced VEGF production through an src-dependent pathway and MAPK/ERK signal pathways, and both of VEGF and IL-1b eta up-regulated vascular angiogenesis and permeability [37–39].

Angiogenesis, migration, and proliferation are the most representative indices of endothelial cell function. The angiogenic growth factors VEGF and PDGF can

Fig. 7 A. Effects of static or activated microglia on proliferation of RMECs. RMECs were cocultured with microglia (with or without LPS) for 24 h, WST-1 reagent was used to evaluate RMECs proliferation ability. We found that both static and activated microglia induced RMECs proliferation, and LPS further enhanced the stimulatory effect of microglia on RMECs. B. Effects of static or activated microglia on permeability and phenotype of RMECs. For evaluation of permeability and phenotype of RMECs, after cocultured with microglia (with or without LPS) for 24 h, we collected RMECs and tested protein expression of occludin, ZO-1, CD-31, and CD-34. Both static and activated microglia significantly reduced the expression of occludin and ZO-1, markers of cell permeability, in RMECs compared with RMECs without microglia. Regarding phenotype, both static and activated microglia reduced CD31 and increased CD34 expression, which are endothelial markers, in RMECs (B). *P < 0.05 using one-way ANOVA. **P < 0.01 using one-way ANOVA. Abbreviations: Con, control RMECs (i.e., cultured without microglia); MG, RMECs co-cultured with static microglia; LPS-MG, RMECs co-cultured with activated microglia; LPS, lipopolysaccharide; ZO-1, zonula occludens-1.
enhance endothelial angiogenesis, migration, and the proliferation [30, 39–41]. We showed that microglia promoted tube formation, wound healing, and proliferation of co-cultured RMECs, and activated microglia significantly enhanced these effects, in accordance with increased VEGF and PDGF levels.

Hyperpermeability is an important change associated with vascular dysfunction in neovascular diseases [42]. The paracellular permeability of the endothelium depends on the integrity of protein complexes involved in the inter-endothelial junctions [43]. ZO-1 and occludin are indispensable components of tight junctions regulated by pro-inflammatory cytokines and growth factors [44–49]. We showed that microglia downregulated ZO-1 and occludin expression, in agreement with previous studies [50–52]. The inhibitory effects of activated microglia on tight junction proteins were stronger than those of static microglia.

CD31 and CD34 are specific markers of endothelial cells. CD31 (also known as platelet/endothelial cell adhesion molecule-1) is a transmembrane protein that is strongly expressed at cell borders and plays a role in supporting the integrity of endothelial cell–cell junctions [53–55]. CD34, a marker of angiogenesis, is a single-chain transmembrane glycoprotein expressed on the surfaces of hematopoietic precursor cells and capillary endothelial cells [56–58]. In this study, we found that microglia downregulated the expression of CD31 but upregulated the expression of CD34 in co-cultured endothelial cells, and activation of the microglia enhanced these effects. This result is additional evidence illustrating the effects of microglia on tight junction proteins and angiogenesis of endothelial cells.

Vascular endothelial cells and microglia interact in direct or indirect ways. In this study, we used the Transwell system to study their indirect contact mainly through evaluating the release of soluble cytokines. Similar approaches have been evaluated in the CNS system. Endothelial angiogenesis and blood-brain barrier (BBB) dysfunction were caused by the soluble tumor necrosis factor α (TNF-α) released from microglial cells [59, 60]. Circulating micro-vesicles containing miR-27a obtained from LPS-stimulated microglia supernatant damaged the tight junction of RMECs under the OGD condition [61]. In addition, the literature shows that microglia and endothelial cells can also directly interact through the interaction of CD200/CD200R and CX3CL1/CX3CR1, by which endothelial cells are able to regulate the function of microglia [62, 63]. The mechanism and pathways need further investigation.

Conclusion
In this study, we demonstrated that co-culturing RMECs with microglia resulted in upregulation of VEGF-A and PDGF-BB expression, angiogenesis, migration, and proliferation and downregulated the expression of tight junction proteins in RMECs, and these effects were significantly enhanced by microglial activation. The mechanisms underlying the effects of microglia on the function of adjacent endothelial cells, including the cytokines/proteins and specific pathways involved, need further clarification.

Abbreviations
IL-1β: Interleukin 1β; LPS: Lipopolysaccharide; MG: Microglia; PDGF-BB: Platelet-derived growth factor-BB; RMECs: Retinal microvascular endothelial cells; TNFa: Tumor necrosis factor; VEGF-A: Vascular endothelial growth factor-A; vWF: von-Willebrand factor; WST-1: Water soluble tetrazolium-1; ZO-1: Zonula occludens-1

Acknowledgements
Thanks for the contributions of all the authors.

Funding
This work was supported by funding from the National Natural Science Foundation for Young Scholars of China (nos. 81300781,81400410,81308805,81700862), National Natural Science Foundation of China (nos. 81570854).

Availability of data and materials
The datasets used and/or analysed during the current study available from the corresponding author on reasonable request.

Authors’ contributions
HW conceived and designed the experiments; XD and RG performed the experiments with the assistance of MZ, HR and QS. XD and RG analyzed the data and prepared the manuscript. GX aided the technical support. GX and QS helped revise the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate
This study and all relevant experimental procedures were approved by the Animal Ethics Committee of the Eye and ENT Hospital of Fudan University, China, and were conducted in accordance with the Association for Research in Vision and Ophthalmology’s statement on the use of animals in ophthalmic and vision research.

Consent for publication
Not applicable.

Competing interests
All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers’ bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements) or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Department of Ophthalmology, Eye and ENT Hospital of Fudan University, 83 Fen Yang Road, Shanghai 200031, People’s Republic of China. 2Institute of Eye Research, Eye and ENT Hospital of Fudan University, Shanghai, China. 3Key Laboratory of Myopia of State Health Ministry (Fudan University), Shanghai, China. 4Shanghai Key Laboratory of Visual Impairment and Restoration(Fudan University), Shanghai, China.
References

1. Li L, Zhen N, Heiduschka P. The microglia in healthy and diseased retina. Exp Eye Res. 2015;131:16–30.
2. Zhu SH, et al. Paenflorin suppressed high glucose-induced retinal microglia MIP-9 expression and inflammatory response via inhibition of TLR4/NF-kappaB pathway through Upregulation of SOCS3 in diabetic retinopathy. Inflammation. 2017;40(5):1475–86.
3. Ma W, et al. Microglia in the mouse retina alter the structure and function of retinal pigmented epithelial cells: a potential cellular interaction relevant to AMD. PLoS One. 2009;4(1):e7945.
4. Rutar M, et al. Analysis of complement expression in light-induced retinal degeneration: synthesis and deposition of C3 by microglia/macrophages is associated with focal photoreceptor degeneration. Invest Ophthalmol Vis Sci. 2011;52(8):5407–53.
5. Gullapalli VK, et al. Hematopoietically derived retinal perivascular microglia initiate uveoretinitis in experimental autoimmune uveitis. Graefes Arch Clin Exp Ophthalmol. 2002;238(4):319–25.
6. Eelen G, et al. Endothelial cell metabolism in normal and diseased vasculature. Circ Res. 2015;116(7):1231–44.
7. Armulik A, Abramsson A, Betsholtz C. Endothelial/pericyte interactions. Circ Res. 2005;97(6):132–23.
8. Grigby JG, et al. The role of microglia in diabetic retinopathy. J Ophthalmol. 2014;2014:95783.
9. Adamis AP, Berman AJ. Immunological mechanisms in the pathogenesis of diabetic retinopathy. Semin Immunopathol. 2008;30(2):159–65.
10. Rutter C, Brandle E, Gerber AA. Circular RNAs: a new class of endogenous non-coding RNA molecules. Adv Exp Med Biol. 2016;907:53–65.
11. Zeng HY, Green WR, Tao MO. Microglial activation in human diabetic retinopathy. Arch Ophthalmol. 2008;126(2):227–32.
12. Ding X, et al. Activated microglia induce the production of reactive oxygen species and promote apoptosis of co-cultured retinal microvascular pericytes. Graefes Arch Clin Exp Ophthalmol. 2017;255(5):777–84.
13. Wong JS, Aiello LP. Diabetic retinopathy. Ann Acad Med Singap. 2000;29(6):745–752.
14. van der Wijk AE, et al. Spatial and temporal recruitment of the monocyte/macrophage lineage: phenotypic plasticity and function in the retina. J Orthop Res. 2009;27(2):229–35.
15. Shin MR, et al. TNF-alpha and LPS activate angiogenesis via VEGF and SIRT1 signalling in human dental pulp cells. Int Endod J. 2015;48(7):705–16.
16. Tipton DA, Christian J, Blumer A. Effects of cranberry components on IL-1beta-stimulated production of IL-6, IL-8 and VEGF by human TMJ synovial fibroblasts. Arch Oral Biol. 2016;68(88–96).
17. Huang F, et al. MAPK/ERK pathway involved expression of COX-2 and VEGF by IL-1beta induced in human endometriosis stromal cells in vitro. Int J Exp Pathol. 2013;10;2019:2129–36.
18. Sheikpanbabu S, et al. Silver nanoparticles inhibit VEGF-and IL-1beta-induced vascular permeability via Src dependent pathway in porcine retinal endothelial cells. J Nanobiotechnol. 2009;7/8.
19. Suijburg CA, et al. Components of Paeoniflorin suppressed high glucose-induced retinal microglia MIP-9 expression and inflammatory response via inhibition of TLR4/NF-kappaB pathway through Upregulation of SOCS3 in diabetic retinopathy. Inflammation. 2017;40(5):1475–86.
20. Yousif NM, et al. Activation of EP2 receptor suppresses poly(I:C) and LPS-induced NF-kappaB activation. Science. 2005;309(5742):1854–9.
21. Busch S, et al. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J. 2004;18(2):2338–40.
22. Siedlecki J, et al. Combined VEGF and PDGF inhibition for neovascular AMD: anti-angiogenic properties of axitinib on human endothelial cells and pericytes in vitro. Graefes Arch Clin Exp Ophthalmol. 2017;255(5):963–72.
23. Hermann JL, et al. IL-6 and TGF-alpha costimulate mesenchymal stem cell vascular endothelial growth factor production by ERK-, JNK-, and PI3K-mediated mechanisms. Shock. 2011;35(5):512–6.
24. Vinores SA, et al. Upregulation of vascular endothelial growth factor (VEGF) in the retina of transgenic mice overexpressing interleukin-1beta (IL-1beta) in the lens and mice undergoing retinal degeneration. Histol Histopathol. 2003;18(3):797–810.
25. Chen WH, Chen Y, Cui GH. Effects of TNF-alpha and curcumin on the expression of VEGF in Raji and U937 cells and on angiogenesis in ECV304 cells. Chin Med J. 2005;118(24):2052–7.
26. Zhou P, et al. Attenuation of TNF-alpha-induced inflammatory injury in endothelial cells by Ginsenoside Rb1 via inhibiting NF-kappaB, JNK and p38 signaling pathways. Front Pharmacol. 2017;8:464.
27. Onba T, et al. TNF-alpha-induced NF-kappaB signaling reverses age-related declines in VEGF induction and angiogenic activity in intervertebral disc tissues. J Orthop Res. 2009;27(2):229–35.
28. Ding X, et al. Activated microglia induce the production of reactive oxygen species and promote apoptosis of co-cultured retinal microvascular pericytes. Graefes Arch Clin Exp Ophthalmol. 2008;238(4):735–45.
29. Zhang L, et al. Diesel exhaust particles modulate vascular endothelial cell traction force and permeability changes in human diabetic retinopathy. Invest Ophthalmol Vis Sci. 2015;56(3):1160–7.
30. Vinals F, Poussysegur J. Transforming growth factor beta1 (TGF-beta1) promotes endothelial cell survival during in vitro angiogenesis via an autocrine mechanism implicating TGF alpha-signaling. Mol Cell Biol. 2001;21(21):7219–31.
31. Mathews MK, et al. Vascular endothelial growth factor and vascular permeability changes in human diabetic retinopathy. Invest Ophthalmol Vis Sci. 1997;38(13):2729–41.
32. Matsunaga T, et al. Enhancement of endothelial barrier permeability by Mitragynine. Biol Pharm Bull. 2017;40(10):1779–83.
33. Li Y, et al. TNFalpha alters occludin and cerebral endothelial permeability: role of p38MAPK. PLoS One. 2017;12(2):e0170346.
34. Zhang L, et al. Vascular endothelial growth factor increases GEnC permeability by affecting the distributions of occludin, ZO-1 and tight junction assembly. Eur Rev Med Pharmacol Sci. 2015;19(14):2621–7.
35. Li R, et al. Diesel exhaust particles modulate vascular endothelial cell permeability: implication of ZO-1 expression. Toxicol Lett. 2010;197(3):163–8.
36. Abbuschato TJ, et al. Nicotine and cotinine modulate cerebral microvascular permeability and protein expression of ZO-1 through nictinic acetylcholine receptors expressed on brain endothelial cells. J Pharm Sci. 2002;91(12):2525–38.
37. Murakami T, Felinski EA, Antonetti DA. Occludin phosphorylation and ubiquitination regulate tight junction trafficking and vascular endothelial growth factor-induced permeability. J Biol Chem. 2009;284(31):21036–46.
38. Harhaj NS, et al. Poly(ADP-ribose) polymerase-1 regulates microglia-mediated decrease of endothelial tight junction integrity. Neurochem Int. 2017;108:266–71.
39. Klingshoffer RA, et al. Platelet-derived growth factor-dependent activation of phosphatidylinositol 3-kinase is regulated by receptor binding of SH2-domain-containing proteins which influence Ras activity. Mol Cell Biol. 1996;16(10):5905–14.
40. Erber R, et al. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J. 2004;18(2):2338–40.
41. Lardon F, et al. Classical activation of microglia in CD200-deficient mice is a consequence of blood brain barrier permeability and infiltration of peripheral cells. Brain Behav Immun. 2013;34:86–97.
42. Mehrabadi AR, et al. Poly(ADP-ribose) polymerase-1 regulates microglia-mediated decrease of endothelial tight junction integrity. Neurochem Int. 2017;108:266–71.
43. Figure 1. Diagram depicting the mechanisms underlying VEGF-induced vascular permeability changes.
44. Figure 2. Bar graph showing the relative levels of VEGF expression in various tissues.
45. Figure 3. Flowchart outlining the steps involved in the VEGF signaling pathway.
46. Figure 4. Heat map illustrating the expression pattern of VEGF in different conditions.

Received: 28 March 2018 Accepted: 14 August 2018
Published online: 17 September 2018
52. Sumi N, et al. Lipopolysaccharide-activated microglia induce dysfunction of the blood-brain barrier in rat microvascular endothelial cells co-cultured with microglia. Cell Mol Neurobiol. 2010;30(2):247–53.

53. Privratsky JR, Newman PJ. PECAM-1: regulator of endothelial junctional integrity. Cell Tissue Res. 2014;355(3):607–19.

54. RayChaudhury A, et al. Regulation of PECAM-1 in endothelial cells during cell growth and migration. Exp Biol Med (Maywood). 2001;226(7):686–91.

55. Rothermel TA, Engelhardt B, Sheibani N. Polyoma virus middle-T-transformed PECAM-1 deficient mouse brain endothelial cells proliferate rapidly in culture and form hemangiomas in mice. J Cell Physiol. 2005;202(1):230–9.

56. Jackson DE, et al. Platelet endothelial cell adhesion molecule-1 (PECAM-1/CD31) is associated with a naive B-cell phenotype in human tonsils. Tissue Antigens. 2000;56(2):105–16.

57. Vasconcelos MG, et al. Expression of CD34 and CD105 as markers for angiogenesis in oral vascular malformations and pyogenic granulomas. Eur Arch Otorhinolaryngol. 2011;268(8):1213–7.

58. Yao Y, et al. Endoglin (CD105) expression in angiogenesis of primary hepatocellular carcinomas: analysis using tissue microarrays and comparisons with CD34 and VEGF. Ann Clin Lab Sci. 2007;37(1):39–48.

59. Li Y, et al. Ephrin-A3 and ephrin-A4 contribute to microglia-induced angiogenesis in brain endothelial cells. Anat Rec (Hoboken). 2014;297(10):1908–18.

60. Nishioku T, et al. Tumor necrosis factor-alpha mediates the blood-brain barrier dysfunction induced by activated microglia in mouse brain microvascular endothelial cells. J Pharmacol Sci. 2010;112(2):251–4.

61. Lyu Y, et al. Microvesicles derived from LPS-induced microglia aggravate the injury of tight junction in rat brain microvascular endothelial cells under oxygen-glucose deprivation. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2018;34(3):211–7.

62. Liu Y, et al. Role of microglia-neuron interactions in diabetic encephalopathy. Ageing Res Rev. 2018;42:28–39.

63. Jerath MR, et al. Dual targeting of CCR2 and CX3CR1 in an arterial injury model of vascular inflammation. Thromb J. 2010;8:14.